BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 10049047)

  • 1. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
    Manley R; Cochrane J; McDonald M; Rigby S; Moore A; Kirk A; Clarke S; Crossen PE; Morris CM; Patton WN
    Leukemia; 1999 Jan; 13(1):126-9. PubMed ID: 10049047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-lymphoid/myeloid stem cell origin in Ph-positive acute leukemia with myeloid markers.
    Akashi K; Taniguchi S; Nagafuji K; Harada M; Shibuya T; Hayashi S; Gondo H; Niho Y
    Leuk Res; 1993 Jul; 17(7):549-55. PubMed ID: 8326735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive cytogenetic studies of clonality following interferon-alpha therapy in chronic myeloid leukemia occurring in monosomic cells in a patient with Turner syndrome mosaic.
    Takeshita A; Shinjo K; Yamashita M; Fujisawa S; Naito K; Ohnishi K; Takahashi K; Matsui H; Ohno R
    Leukemia; 1999 Nov; 13(11):1749-53. PubMed ID: 10557048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
    Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
    Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
    Brizard F; Chomel JC; Veinstein A; Rivet J; Giraud C; Kitzis A; Guilhot F; Brizard A
    Leukemia; 1998 Jul; 12(7):1076-80. PubMed ID: 9665193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of BCR/ABL fusion gene in CML: a preliminary report.
    Rerkamnuaychoke B; Kangwanpong D; Jootar S; Puranakanitstha C
    Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():197-200. PubMed ID: 8629106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
    González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
    Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
    Corsetti MT; Lerma E; Dejana A; Basta P; Ferrara R; Benvenuto F; Vassallo F; Abate M; Piaggio G; Parodi C; Sessarego M; Li Pira G; Manca F; Carella AM
    Leukemia; 1999 Jul; 13(7):999-1008. PubMed ID: 10400414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
    Sick C; Schultheis B; Pasternak G; Kottke I; Hörner S; Heissig B; Hehlmann R
    Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
    Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
    Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
    Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.
    Fujie H; Tsuchiya S; Morita S; Itano M; Yambe T; Ohasi Y; Minegishi N; Minegishi M; Satou T; Konno T
    Leukemia; 1994 Sep; 8(9):1592-5. PubMed ID: 8090037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears.
    Cabot GP; Bentz M; Scholl C; Moos M; Fischer K; Lichter P; Döhner H
    Cancer Genet Cytogenet; 1996 Apr; 87(2):107-11. PubMed ID: 8625254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.